A166
- Generic Name
- A166
- Drug Type
- Biotech
- Background
A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker.
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
Phase 3
Active, not recruiting
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Target Recruit Count
- 365
- Registration Number
- NCT06968585
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of A166 in Patients With Advanced Solid Malignant Tumors
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 120
- Registration Number
- NCT05311397
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Phase 1
Completed
- Conditions
- HER-2 Gene AmplificationSalivary Gland TumorLung CancerRare DiseasesHead and Neck CancerBile Duct CancerProstate CancerRecurrent Prostate CancerRectal CancerRectal Cancer Stage III
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03602079
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
🇺🇸Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath